Spots Global Cancer Trial Database for primary peritoneal cavity cancer
Every month we try and update this database with for primary peritoneal cavity cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | NCT00005046 | Ovarian Cancer Primary Periton... | chemotherapy paclitaxel | 21 Years - | GOG Foundation | |
| Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | NCT00569673 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim pegfilgrastim docetaxel trabectedin | 18 Years - 120 Years | GOG Foundation | |
| Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | NCT00903396 | Anal Cancer Carcinoma of th... Colorectal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Gastrointestina... Liver Cancer Nausea and Vomi... Pancreatic Canc... Primary Periton... Small Intestine... | palonosetron hy... placebo | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer | NCT00601406 | Breast Cancer Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Primary Periton... Prostate Cancer Sarcoma Vaginal Cancer Vulvar Cancer | gene expression... gene rearrangem... polymorphism an... laboratory biom... radiation thera... | - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| FT516 and IL2 With Enoblituzumab for Ovarian Cancer | NCT04630769 | Ovarian Cancer Fallopian Tube ... Primary Periton... | IP FT516 Enoblituzumab IL-2 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00003385 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin paclitaxel pegylated lipos... | - | GOG Foundation | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors | NCT00066651 | Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton... | SS1(dsFv)-PE38 ... | 18 Years - | National Cancer Institute (NCI) | |
| Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer | NCT00003670 | Ovarian Cancer Primary Periton... | arzoxifene hydr... | 18 Years - | Eli Lilly and Company | |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | NCT00093496 | Primary Periton... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | gemcitabine hyd... tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | NCT00041041 | Primary Periton... Recurrent Ovari... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | NCT00005029 | Ovarian Cancer Primary Periton... | topotecan hydro... | - 120 Years | GOG Foundation | |
| Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum | NCT00012090 | Fallopian Tube ... Ovarian Cancer Primary Periton... | bicalutamide goserelin aceta... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00004064 | Fallopian Tube ... Ovarian Cancer Primary Periton... | oregovomab | 18 Years - | National Cancer Institute (NCI) | |
| Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00041080 | Fallopian Tube ... Primary Periton... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | tamoxifen citra... thalidomide laboratory biom... | - | National Cancer Institute (NCI) | |
| CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00096239 | Fallopian Tube ... Ovarian Cancer Primary Periton... | CP-547,632 | 18 Years - | National Cancer Institute (NCI) | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum | NCT00005860 | Cancer | floxuridine leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | NCT01100372 | Fallopian Tube ... Ovarian Cancer Primary Periton... | gemcitabine hyd... liposome-encaps... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer | NCT00003439 | Cancer | recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00023907 | Ovarian Cancer Primary Periton... | paclitaxel | - | GOG Foundation | |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00004064 | Fallopian Tube ... Ovarian Cancer Primary Periton... | oregovomab | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | NCT00005029 | Ovarian Cancer Primary Periton... | topotecan hydro... | - 120 Years | GOG Foundation | |
| Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00022659 | Primary Periton... Recurrent Ovari... Stage IV Ovaria... | bevacizumab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00016289 | Primary Periton... Recurrent Ovari... | recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | NCT00562640 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim therapeutic aut... cyclophosphamid... laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT00114166 | Fallopian Tube ... Ovarian Cancer Primary Periton... | topotecan hydro... | 18 Years - 120 Years | GOG Foundation | |
| Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | NCT00005046 | Ovarian Cancer Primary Periton... | chemotherapy paclitaxel | 21 Years - | GOG Foundation | |
| Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy | NCT00003634 | Fallopian Tube ... Ovarian Cancer Primary Periton... | oregovomab | 18 Years - | National Cancer Institute (NCI) | |
| S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00872989 | Fallopian Tube ... Ovarian Cancer Primary Periton... | docetaxel vandetanib | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers | NCT00002538 | Fallopian Tube ... Ovarian Cancer Primary Periton... | laparoscopic su... | 18 Years - | GOG Foundation | |
| Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT00019461 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboxyamidotri... chemotherapy | 18 Years - | National Cancer Institute (NCI) | |
| Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | NCT06342986 | Gynecologic Can... Ovarian Cancer Fallopian Tube ... Primary Periton... | FT536 Fludarabine CY | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | NCT00028912 | Fallopian Tube ... Ovarian Cancer Primary Periton... | bortezomib carboplatin | - | National Cancer Institute (NCI) | |
| VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00436501 | Fallopian Tube ... Malignant Tumor... Recurrent Ovari... | docetaxel ziv-aflibercept laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer | NCT00002894 | Ovarian Cancer Primary Periton... | carboplatin cisplatin paclitaxel | - | National Cancer Institute (NCI) | |
| VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00436501 | Fallopian Tube ... Malignant Tumor... Recurrent Ovari... | docetaxel ziv-aflibercept laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| FT516 and IL2 With Enoblituzumab for Ovarian Cancer | NCT04630769 | Ovarian Cancer Fallopian Tube ... Primary Periton... | IP FT516 Enoblituzumab IL-2 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | NCT00081276 | Primary Periton... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | triapine cisplatin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors | NCT00004082 | Endometrial Can... Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin docetaxel gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | NCT00113373 | Primary Periton... Recurrent Ovari... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy | NCT00005836 | Ovarian Cancer Primary Periton... | oxaliplatin | - | National Cancer Institute (NCI) | |
| Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00041080 | Fallopian Tube ... Primary Periton... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | tamoxifen citra... thalidomide laboratory biom... | - | National Cancer Institute (NCI) | |
| Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer | NCT00769405 | Colorectal Canc... Primary Periton... | fluorouracil leucovorin calc... oxaliplatin hyperthermia tr... | 18 Years - 70 Years | UNICANCER | |
| CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | NCT00305838 | Fallopian Tube ... Ovarian Cancer Primary Periton... | tamoxifen citra... diagnostic labo... | - | National Cancer Institute (NCI) | |
| Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | NCT00039585 | Fallopian Tube ... Ovarian Cancer Primary Periton... | imatinib mesyla... | - | National Cancer Institute (NCI) | |
| Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | NCT00006267 | Ovarian Cancer Primary Periton... | rubitecan | - | GOG Foundation | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | NCT00031954 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin gemcitabine hyd... paclitaxel | 18 Years - 120 Years | AGO Study Group | |
| Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00004012 | Fallopian Tube ... Ovarian Cancer Primary Periton... | capecitabine | - | Memorial Sloan Kettering Cancer Center | |
| Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer | NCT00003670 | Ovarian Cancer Primary Periton... | arzoxifene hydr... | 18 Years - | Eli Lilly and Company | |
| Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00838656 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin gemcitabine hyd... paclitaxel | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer | NCT00003322 | Ovarian Cancer Primary Periton... | cisplatin paclitaxel quality-of-life... | - | GOG Foundation | |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | NCT00005026 | Ovarian Cancer Primary Periton... | carboplatin paclitaxel topotecan hydro... | - | GOG Foundation | |
| Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum | NCT00012090 | Fallopian Tube ... Ovarian Cancer Primary Periton... | bicalutamide goserelin aceta... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | NCT00058435 | Fallopian Tube ... Ovarian Cancer Primary Periton... | abagovomab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00096239 | Fallopian Tube ... Ovarian Cancer Primary Periton... | CP-547,632 | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer | NCT00003136 | Ovarian Cancer Primary Periton... | filgrastim amifostine trih... carboplatin cyclophosphamid... peripheral bloo... | - 65 Years | University of Chicago | |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer | NCT00003704 | Cancer | capecitabine radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum | NCT00003160 | Fallopian Tube ... Ovarian Cancer Primary Periton... | paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | NCT00003880 | Ovarian Cancer Primary Periton... | recombinant ade... carboplatin paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer | NCT00087191 | Advanced Adult ... Carcinoma of th... Fallopian Tube ... Gastrointestina... Localized Extra... Localized Gallb... Localized Gastr... Localized Resec... Localized Unres... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Primary Periton... Recurrent Adult... Recurrent Adult... Recurrent Colon... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Small... Recurrent Uteri... Regional Gastro... Small Intestine... Small Intestine... Small Intestine... Stage 0 Non-sma... Stage I Adult S... Stage I Colon C... Stage I Gastric... Stage I Non-sma... Stage I Ovarian... Stage I Ovarian... Stage I Pancrea... Stage I Rectal ... Stage I Uterine... Stage II Adult ... Stage II Colon ... Stage II Gastri... Stage II Non-sm... Stage II Ovaria... Stage II Ovaria... Stage II Pancre... Stage II Rectal... Stage II Uterin... Stage III Adult... Stage III Colon... Stage III Gastr... Stage III Ovari... Stage III Ovari... Stage III Pancr... Stage III Recta... Stage III Uteri... Stage IIIA Non-... Stage IIIB Non-... Stage IV Adult ... Stage IV Colon ... Stage IV Gastri... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Stage IV Uterin... Unresectable Ex... Unresectable Ga... | EF5 motexafin lutet... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | NCT00066729 | Fallopian Tube ... Ovarian Cancer Primary Periton... | NY-ESO-1 peptid... | 18 Years - | Ludwig Institute for Cancer Research | |
| Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | NCT00031954 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin gemcitabine hyd... paclitaxel | 18 Years - 120 Years | AGO Study Group | |
| Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | NCT00005025 | Fallopian Tube ... Ovarian Cancer Primary Periton... | herpes simplex ... ganciclovir | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00003636 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin cisplatin conventional su... neoadjuvant the... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00023699 | Ovarian Cancer Primary Periton... | gefitinib | - | National Cancer Institute (NCI) | |
| Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | NCT00041041 | Primary Periton... Recurrent Ovari... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | NCT00072267 | Fallopian Tube ... Ovarian Cancer Primary Periton... | 7-hydroxystauro... topotecan hydro... | 18 Years - | University Health Network, Toronto | |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer | NCT00601406 | Breast Cancer Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Primary Periton... Prostate Cancer Sarcoma Vaginal Cancer Vulvar Cancer | gene expression... gene rearrangem... polymorphism an... laboratory biom... radiation thera... | - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer | NCT00003378 | Ovarian Cancer Primary Periton... | carboplatin gemcitabine hyd... paclitaxel | 18 Years - 80 Years | GOG Foundation | |
| AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00574951 | Fallopian Tube ... Ovarian Cancer Primary Periton... | motesanib dipho... | 18 Years - 120 Years | GOG Foundation | |
| Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT00429793 | Fallopian Tube ... Primary Periton... Recurrent Ovari... | temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer | NCT00005944 | Colorectal Canc... Metastatic Canc... Primary Periton... | chemotherapy fluorouracil leucovorin calc... mitomycin C conventional su... laparoscopic su... | 0 Years - 70 Years | UNICANCER | |
| Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | NCT00075712 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin paclitaxel adjuvant therap... conventional su... neoadjuvant the... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
